UI 089/UI 090/UI 091/UI 092
Alternative Names: UI-089/UI-090/UI-091/UI-092Latest Information Update: 12 Mar 2024
At a glance
- Originator Korea United Pharm Inc
- Class Antihypertensives
- Mechanism of Action Lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 05 Mar 2024 UI 089/UI 090/UI 091/UI 092 is available for licensing as of 05 Mar 2024. https://www.kup.co.kr/main.do
- 04 Mar 2024 Early research in Unspecified in South Korea (unspecified route) before March 2024 (Korea United Pharm pipeline, March 2024)
- 04 Mar 2024 Korea United Pharm Inc plans to launch UI 089/UI 090/UI 091/UI 092 in 2027 (Korea United Pharm pipeline, March 2024)